Spots Global Cancer Trial Database for Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors
Official Title: A Phase 1 Study to Evaluate the Safety and Tolerability of GS-0201 as Monotherapy and in Combination in Adults With Advanced Solid Tumors
Study ID: NCT06167317
Conditions
Study Description
Brief Summary: The main goal of this first in human (FIH) study is to learn about the safety and dosing of GS-0201 when given alone or in combination with sacituzumab govitecan (SG) in participants with advanced solid tumors. The primary objectives of this study are to: * To assess the safety and tolerability of GS-0201 as monotherapy and in combination with SG in participants with selected advanced solid tumors * To identify the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of GS-0201 as monotherapy and the MTD and/or the RP2D and dosing schedule of GS-0201 in combination with SG in participants with selected advanced solid tumors
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Dana-Farber Cancer Institute, Newton, Massachusetts, United States
NEXT Austin, Austin, Texas, United States
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
NEXT Dallas, Irving, Texas, United States
Rambam Health Care Campus, Haifa, , Israel
Tel Aviv Sourasky Medical Center, Tel Aviv, , Israel
Chaim Sheba Medical Center, Tel Hashomer, , Israel
Contact Details
Name: Gilead Study Director
Affiliation: Gilead Sciences
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
